Compare HERE & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HERE | OABI |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | China | United States |
| Employees | 714 | 89 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.5M | 225.9M |
| IPO Year | N/A | N/A |
| Metric | HERE | OABI |
|---|---|---|
| Price | $3.37 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 201.5K | ★ 288.0K |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | $79.29 | $64.69 |
| P/E Ratio | $2.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.89 | $1.22 |
| 52 Week High | $5.80 | $2.22 |
| Indicator | HERE | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 29.70 |
| Support Level | $2.89 | $1.32 |
| Resistance Level | $4.71 | $1.72 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 56.98 | 10.17 |
Here Group Ltd is dedicated to creating collectible pop toys that evoke joy and emotional resonance. The group design and compelling storytelling, which provide users with a collecting experience that blends artistic value with emotional warmth, continuously convey a joyful and immersive brand culture. Adhering to the brand philosophy of joy, integrity, wonder, and co-creation, the company is building a vibrant ecosystem connecting creativity and emotion, working hand-in-hand with overall toy enthusiasts to create, share, and transmit dreams.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.